People

Smart & Biggar is Canada’s largest and highest ranked intellectual property firm. Our reputation and strength is a measure of the quality of our people, and we are proud to have the broadest and deepest bench for IP in Canada. With over 100 lawyers, patent agents and trademark agents, we offer legal expertise and technological knowledge across a wide range of industries and scientific and engineering disciplines, with leaders in every field.

Services

Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP. Our highly skilled team of lawyers, patent agents and trademark agents advise clients on a wide variety of strategic business, brand and technology matters leveraging their deep expertise in intellectual property to help them succeed with IP.

Industries

Across all industries, intellectual property is at the heart of innovation and is key to accelerating business value and growth. Developing a clear IP strategy and knowing how to tap and leverage IP to align with business goals can unlock competitive advantages and make the difference between industry leaders and followers.

Insights

At the forefront of IP in Canada, and actively involved as leaders in industry committees and associations, we stay up-to-date and proactively report on the latest developments in intellectual property law in Canada and around the world. Breaking IP news, changes in the law, important new decisions, and information on key IP issues are provided here through our IP publications and resources.

Careers

Many of the world's most commercially important innovators and most prominent brands trust Smart & Biggar to protect and enforce their IP and to provide them with strategic IP counsel. We have developed a reputation as a firm of talented lawyers and patent and trademark agents with integrity, business savvy and tremendous acumen. That’s why we look for the brightest people with combined talent and strengths in law, business, science and technology.

Who we are

Smart & Biggar is widely recognized as Canada’s leading firm for intellectual property, and with over 100 lawyers, patent agents and trademark agents in five offices, we are also Canada’s largest firm focused purely on IP and related specialty areas.

Rx IP - Regulatory

Health Canada Annual Drug Submission Performance Reports released

Brandon Heard

August 27, 2020

Update: On September 1, 2020, BRDD revised its Report to correct the “Biosimilars: Market Authorizations” tables.

The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD; formerly BGTD) and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission Performance Annual Reports for Fiscal Year 2019-2020. The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical, and non-prescription and disinfectant drug submission review activity over five consecutive fiscal years (April 1 to March 31) from 2015-2016 to 2019-2020.

Related Person

Brandon Heard
Associate
- Smart & Biggar LLP
Barrister and Solicitor
- T:647.798.0020
- brheard@smartbiggar.ca
- Toronto
Brandon Heard
Associate
Brandon brings a sharp, analytical perspective and broad understanding of law and economics to his IP litigation practice. He is involved in all aspects of litigation, including drafting court documen...
Read More

Related Publications & Articles

Federal Court of Appeal refuses to grant stay of Federal Court decision remanding Health Canada’s refusal of SHINGRIX CSP

Andrea Berenbaum
September 28, 2020
The FCA recently dismissed a motion brought by the Minister of Health for stay of a judgment of the FC that held Health Canada’s refusal to issue a CSP in respect of Canadian Patent No. 2,600,905 (905...
Read More
Federal Court finds reasonable Health Canada’s decision that enantiomer of previously approved drug not entitled to data protection

Eleanor Wilson
September 28, 2020
On September 18, 2020, the Federal Court dismissed Janssen’s application for judicial review of a decision of the Minister of Health (Minister) denying Janssen data protection for its drug SPRAVATO: J...
Read More
New Interim Order for COVID-19 drugs has wide-reaching impact, allowing Minister to unilaterally expand indication for non-COVID-19 drugs

Alice Tseng and Nancy Pei
September 29, 2020
On September 16, 2020, Canada’s Minister of Health approved an Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (the Interim Order), which introd...
Read More

People

Search People